Papers
2
Total Citations
9
H-Index
2
About
I-Hsing Tsai is a leading medical physicist whose research focuses on radiation oncology, stereotactic body radiotherapy (SBRT), and secondary cancer risk assessment. Dr. Tsai’s major contributions lie in evaluating the safety and efficacy of advanced treatment systems, particularly the CyberKnife M6 platform. In a pivotal 2020 study, Tsai assessed lifetime secondary cancer risk in lung cancer patients after SBRT using the CyberKnife M6 with a lung-optimized treatment module, providing critical data that helps clinicians balance tumor control with long-term radiation safety. Another key 2019 investigation compared plan quality and secondary cancer risk for benign intracranial lesions treated with CyberKnife radiosurgery, examining MLC-based versus IRIS-based plans. This work has been cited 5 and 4 times respectively, reflecting its growing influence in the field. Tsai’s research is notable for integrating dosimetric analysis with clinical outcomes, offering practical guidance for optimizing treatment planning. By quantifying radiation-induced risks, Tsai helps shape safer protocols for both lung cancer and intracranial radiosurgery, making a tangible impact on patient care and radiation oncology practice.
Research Focus
Key Achievements
Top Papers
- 1
- 2